Rhodia continues focus on core activities

French chemicals company Rhodia is to sell its UK-based brewing and
enzymes businesses to US biotech company Genencor International in
a bid to strengthen its focus on food additives.

French chemicals company Rhodia is to sell its UK-based brewing and enzymes businesses to US biotech company Genencor International in a bid to strengthen its focus on food additives.

Rhodia Food, which supplies additives to the dairy, desserts, beverages and nutraceuticals sectors, said enzyme production is not a core technology for the unit.

"This transaction will enable Rhodia to further exceed the target announced at the beginning of 2002 to generate a total of €500 million from divestitures,"​ said the company in a statement.

The divestment is part of the current Rhodia strategy to re-align its portfolio and develop 'value-added' solutions for customers.

The brewing and enzymes production generated sales of around €17 million in 2001 which included a significant distribution business for Genencor, said Rhodia.

Last week the company also announced that it has sold its European industrial and commercial activities related to basic chemicals to Bain Capital, a private investment firm. In November, the companies signed an agreement to divest these non-core chemical intermediates - including phenol, hydrochloric acid, and soda ash.

Rhodia​ generated net sales of €7.2 billion in 2001.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...